Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

27

Revenue 2017

Gilenya

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Gilenya was produced by Novartis.

Cortellis Drugs to Watch in 2020 report

Cortellis Drugs to Watch in 2020 report

To succeed, it will have to differentiate from its direct competitors, particularly the first-in-class S1P1 agonist Gilenya, by leveraging potential cardiovascular safety advantages.

J&J aims for US approval of MS drug ponesimod

J&J aims for US approval of MS drug ponesimod If approved, ponesimod will compete directly with Novartis’ S1P receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod), which is approved for secondary progressive forms of MS only ... There is also the

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

J&J’s ponesimiod tops Aubagio in head-to-head MS trial S1P receptor modulator franchise based on Gilenya(fingolimod) and recently-launched follow-up  Mayzent(siponimod), which for now is approved for secondary progressive forms of MS only. ... There is also a looming threat of generic competition to Gilenya

Merck takes evobrutinib for MS into phase 3, on mixed data

Merck takes evobrutinib for MS into phase 3, on mixed data Novartis’ Gilenya (fingolimod) and Sanofi’s Aubagio (teriflunomide).

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi Finally, the panel recommended that Novartis’ multiple sclerosis drug Gilenya (fingolimod) should not be used in pregnant women and in women able to have children who are not using effective contraception

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics